Patents by Inventor Nian E. Zhou

Nian E. Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11083717
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 10, 2021
    Assignee: The Texas A&M University System
    Inventors: Manchi C M Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Publication number: 20200138796
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Manchi CM Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Patent number: 10543200
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, one or more substituted quinols, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, or a combination thereof in an amount and formulation sufficient to sensitize the parasite to the drug, treating infection of a patient by a parasite with a drug, or to prevent symptomatic infection of a patient by a parasite with a drug.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 28, 2020
    Assignee: The Texas A&M University System
    Inventors: Manchi C M Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Publication number: 20190314381
    Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 17, 2019
    Inventors: Manchi CM Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Patent number: 10300071
    Abstract: A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: May 28, 2019
    Assignee: The Texas A&M University System
    Inventors: Manchi C M Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
  • Publication number: 20190142817
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    Type: Application
    Filed: January 16, 2019
    Publication date: May 16, 2019
    Inventors: James C. Sacchettini, Matthew W. Miller, Deeann Wallis, Nian E. Zhou, Theresa W. Fossum
  • Patent number: 10226455
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: March 12, 2019
    Assignee: The Texas A&M University System
    Inventors: James C. Sacchettini, Matthew W. Miller, Deeann Wallis, Nian E. Zhou, Theresa W. Fossum
  • Publication number: 20160354358
    Abstract: Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Inventors: James C. Sacchettini, Matthew W. Miller, Deeann Wallis, Nian E. Zhou, Theresa W. Fossum
  • Patent number: 7091195
    Abstract: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid or a betulinic acid derivative in vivo at the tumor site.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: August 15, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: John M. Pezzuto, Jerome W. Kosmeder, II, Ze-Qi Xu, Nian E. Zhou, Miriam Elaine Goldsmith
  • Publication number: 20040024000
    Abstract: Ditiydropyrimidine derivatives are disclosed, which can be used to inhibit cysteine protease activity.
    Type: Application
    Filed: April 11, 2003
    Publication date: February 5, 2004
    Inventors: Rajeshwar Singh, Andhe V.N. Reddy, Nian E. Zhou, Qizhu Ding, George Thomas, Jadwiga Kaleta, Ronald G. Micetich
  • Patent number: 6034077
    Abstract: In accordance with the present invention, there are provided 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives of the formula: ##STR1## wherein n is 1, 2 or 3; in which R.sub.1, R.sub.2 and R.sub.3 are as defined herein, and salts thereof, which exhibit excellent cysteine proteinase inhibitory activity and which can be used for treatment of different diseases such as muscular dystrophy, myocardial infarction, bone resorption, arthritis, cancer metastasis, pulmonary emphysema, septic shock, cerebral ischemia, memory function, Alzheimer and cataract, malaria, glomerular basement membrane degradation, bacterial infection, inflammatory diseases, parasitic infections, and viral infections.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: March 7, 2000
    Assignee: National Research Council of Canada
    Inventors: Rajeshwar Singh, Nian E. Zhou, Enrico O. Purisima, Ronald G. Micetich
  • Patent number: 5959123
    Abstract: The present invention is based on the discovery that certain 3,4-disubstituted-azetidin-2-one derivatives exhibit excellent cysteine proteinase inhibitory activity which can be used for treatment of different diseases such as muscular dystrophy, myocardial infarction, bone resorption, arthritis, cancer metastasis, pulmonary emphysema, septic shock, cerebral ischemia, memory function, Alzheimer and cataract, malaria, glomerular basement membrane degradation, bacterial infection, inflammatory diseases, parasitic infections, and viral infections. In accordance to the present invention, there is provided a 3,4-disubstituted-azetidin-2-one derivatives of formula I, wherein R.sub.1, R.sub.2 and R.sub.3 are as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: September 28, 1999
    Assignee: Synphar Laboratories, Inc.
    Inventors: Rajeshwar Singh, Nian E. Zhou, Deqi Guo, Ronald G. Micetich
  • Patent number: 5925633
    Abstract: The use of certain 3-substituted-4-oxa-1-azabicyclo?3,2,0! heptan-7-one derivatives of general formula I, ##STR1## or physiologically acceptable salts thereof or isomers thereof, as active ingredients for the preparation of pharmaceutical composition and treatment of different diseases associated with deregulation of cysteine proteases is disclosed.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: July 20, 1999
    Assignee: Synphar Laboraties, Inc.
    Inventors: Rajeshwar Singh, Nian E. Zhou, Deqi Guo, Jadwiga Kaleta, Ronald George Micetich
  • Patent number: 5916887
    Abstract: In accordance with the present invention, there are provided 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives of the formula: ##STR1## wherein n is 1, 2 or 3; in which R.sub.1, R.sub.2 and R.sub.3 are as defined herein, and salts thereof, which exhibit excellent cysteine proteinase inhibitory activity and which can be used for treatment of different diseases such as muscular dystrophy, myocardial infarction, bone resorption, arthritis, cancer metastasis, pulmonary emphysema, septic shock, cerebral ischemia, memory function, Alzheimer and cataract, malaria, glomerular basement membrane degradation, bacterial infection, inflammatory diseases, parasitic infections, and viral infections.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: June 29, 1999
    Assignee: National Research Council of Canada
    Inventors: Rajeshwar Singh, Nian E. Zhou, Enrico O. Purisima, Ronald G. Micetich
  • Patent number: 5905076
    Abstract: Novel 6-substituted amino-4-oxa-1-azabicyclo?3,2,0!heptan-7-one compounds, as well as the pharmaceutically acceptable salts thereof and diastereoisomers thereof, of formula I, ##STR1## are disclosed, which exhibit excellent cysteine protease inhibitory activity and may be used for treatment of different diseases such as muscular dystrophy, arthritis, myocardial infarction, Alzheimer's disease, bacterial infection, common cold, osteroporosis and cancer metastasis.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: May 18, 1999
    Assignee: National Research Council of Canada
    Inventors: Rajeshwar Singh, Nian E. Zhou, Degi Guo, Alan Cameron, Jadwiga Kaleta, Enrico Purisima, Robert Menard, Ronald George Micetich